Anaveon Reports Promising Phase 1 ANV600 Cancer Data at ASCO 2026
BASEL, Switzerland — May 28, 2026 Anaveon announced new clinical data from its Phase 1 EXPAND-1 trial showing encouraging...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BASEL, Switzerland — May 28, 2026 Anaveon announced new clinical data from its Phase 1 EXPAND-1 trial showing encouraging...
SAN FRANCISCO and SUZHOU, China, May 10, 2026 Innovent Biologics, Inc. announced that China’s National Medical Products Administration (NMPA)...
